Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance

Cells. 2022 Oct 11;11(20):3183. doi: 10.3390/cells11203183.

Abstract

The tumor microenvironment plays a key role in progression of tumorigenesis, tumor progression, and metastasis. Accumulating data reveal that dendritic cells (DCs) appear to play a key role in the development and progression of metastatic neoplasia by driving immune system dysfunction and establishing immunosuppression, which is vital for tumor evasion of host immune response. Consequently, in this review, we will discuss the function of tumor-infiltrating DCs in immune cell signaling pathways that lead to treatment resistance, tumor recurrence, and immunosuppression. We will also review DC metabolism, differentiation, and plasticity, which are essential for metastasis and the development of lung tumors. Furthermore, we will take into account the interaction between myeloid cells and DCs in tumor-related immunosuppression. We will specifically look into the molecular immune-related mechanisms in the tumor microenvironment that result in reduced drug sensitivity and tumor relapse, as well as methods for combating drug resistance and focusing on immunosuppressive tumor networks. DCs play a crucial role in modulating the immune response. Especially, as cancer progresses, DCs may switch from playing an immunostimulatory to an inhibitory role. This article's main emphasis is on tumor-infiltrating DCs. We address how they affect tumor growth and expansion, and we highlight innovative approaches for therapeutic modulation of these immunosuppressive DCs which is necessary for future personalized therapeutic approaches.

Keywords: dendritic cells; immunoediting; immunosuppression; metastasis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dendritic Cells*
  • Humans
  • Immune Tolerance
  • Monitoring, Immunologic
  • Neoplasm Recurrence, Local / metabolism
  • T-Lymphocytes*
  • Tumor Microenvironment

Grants and funding

This research was funded by ERAPEDMED/PMT-LC grant—Personalized multimodal therapies for the treatment of lung cancer grant (Grant number: ERAPERMED2020-342) supported by the European network grant and the Greek General Secretariat for Research and Innovation (GSRT).